Skip to content
OpenCapital
Get started

Cytek Biosciences, Inc. CTKB Settlement Liabilities, Current

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%—
Net margin-36.2%—
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%—
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SettlementLiabilitiesCurrent.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s settlement liabilities, current.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s settlement liabilities, current?
Cytek Biosciences, Inc. (CTKB) reported settlement liabilities, current of $2.21M in Q1 2026.
How has Cytek Biosciences, Inc.'s settlement liabilities, current changed year-over-year?
Cytek Biosciences, Inc.'s settlement liabilities, current increased by 29.5% year-over-year, from $1.71M to $2.21M.
What is the long-term trend for Cytek Biosciences, Inc.'s settlement liabilities, current?
Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s settlement liabilities, current has grown at a -16.8% compound annual growth rate (CAGR), from $6.25M to $2.5M.